On December 24, Shanghai Government unveiled the "Work Plan for Developing Medical Artificial Intelligence (2025–2027)" to advance the deep integration of artificial intelligence (AI) with clinical medicine and promote the application of vertical large models in diagnostic support for testing and inspection.

Pertussis is a highly contagious acute respiratory disease that can last for several months and often causes epidemics.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2024.

Personalized, one-on-one health coaching is now available for purchase on questhealth.com. Made available by Pack Health®, a Quest Diagnostics (NYSE: DGX) company that provides evidence-based patient engagement services, questhealth.com's Health Coaching pairs individuals with board-certified health advisers who provide personalized support, resources, and education focused on the individual's unique health goals. The holistic programs focus on several key areas, including general health, weight management, chronic kidney disease, type 2 diabetes, or high cholesterol. For a more tailored experience, individuals can pair Quest lab work with their health coaching to put their diagnostic insights into action.

A. Menarini Diagnostics announces an exclusive Distribution Agreement with Sinocare to register, promote, distribute, and market a new Sinocare 3rd Generation Continuous Glucose Monitoring (CGM) System within reimbursed markets. This landmark agreement grants A. Menarini Diagnostics exclusive rights to introduce this health technology to more than 20 jurisdictions in Europe.

In 2020, the DNBSEQ-T7 Gene Sequencer of Wuhan MGI Technology Co., Ltd. (hereinafter referred to as “MGI”) was approved (Registration No.: G.X.Z.Z. 20,203,220,061).

The US Food and Drug Administration has issued its anticipated guidance for drug and device makers on the use of circulating tumor DNA tests in clinical trials of drugs for early-stage cancer, embracing the increasingly widespread use of these tests to genotype patients as well as their emerging value to enrich trials by identifying patients more likely to benefit from adjuvant or neoadjuvant treatment.

Devyser has received IVDR approval for its non-invasive fetal RHD screening product. This marks the first approval of a Class D product, the highest risk class under the new, comprehensive European regulation that came into force in May 2022. This approval confirms that Devyser’s RHD product meets the stringent safety, efficacy, and quality requirements.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The Egypt Healthcare Authority (EHA), Roche Diagnostics and Roche Pharmaceuticals have signed a memorandum of understanding (MOU) to advance digital pathology in Egypt.

Canon Medical Systems USA is proud to announce the launch of its AI-powered Automation Platform, an advanced, zero-click solution that leverages deep learning technology to streamline clinical workflows. Designed to deliver fast, actionable results, this innovative platform integrates seamlessly from scanner to clinical decision-making, empowering healthcare providers with precise tools to help with patient triage and confident treatment planning.

Suraksha Diagnostic Ltd, an integrated diagnostic chain based in Kolkata, has successfully raised ₹254 crore from anchor investors ahead of its initial public offering (IPO). This significant funding comes just a day before the company opens its IPO for public subscription. The IPO is set to attract considerable attention, given the robust backing from prominent mutual funds and the company’s extensive operational network.